Cargando…

Determining clinically meaningful decline in preclinical Alzheimer disease

OBJECTIVE: To determine the time required for a preclinical Alzheimer disease population to decline in a meaningful way, use estimates of decline to update previous clinical trial design assumptions, and identify factors that modify β-amyloid (Aβ)–related decline. METHODS: In 1,120 cognitively unimp...

Descripción completa

Detalles Bibliográficos
Autores principales:	Insel, Philip S., Weiner, Michael, Mackin, R. Scott, Mormino, Elizabeth, Lim, Yen Ying, Stomrud, Erik, Palmqvist, Sebastian, Masters, Colin L., Maruff, Paul T., Hansson, Oskar, Mattsson, Niklas
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Lippincott Williams & Wilkins 2019
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6669933/ https://www.ncbi.nlm.nih.gov/pubmed/31289148 http://dx.doi.org/10.1212/WNL.0000000000007831

Ejemplares similares

Assessing risk for preclinical β-amyloid pathology with APOE, cognitive, and demographic information
por: Insel, Philip S., et al.
Publicado: (2016)

Association of CSF Aβ(38) Levels With Risk of Alzheimer Disease–Related Decline
por: Cullen, Nicholas, et al.
Publicado: (2022)

Genetic effects on longitudinal cognitive decline during the early stages of Alzheimer’s disease
por: Kumar, Atul, et al.
Publicado: (2021)

Accurate risk estimation of β-amyloid positivity to identify prodromal Alzheimer's disease: Cross-validation study of practical algorithms
por: Palmqvist, Sebastian, et al.
Publicado: (2019)

Mild behavioral impairment and its relation to tau pathology in preclinical Alzheimer’s disease
por: Johansson, Maurits, et al.
Publicado: (2021)

β-amyloid pathology and hippocampal atrophy are independently associated with memory function in cognitively healthy elderly
por: Svenningsson, Anna L., et al.
Publicado: (2019)

Cerebrospinal fluid tau, neurogranin, and neurofilament light in Alzheimer's disease
por: Mattsson, Niklas, et al.
Publicado: (2016)

Prediction of Longitudinal Cognitive Decline in Preclinical Alzheimer Disease Using Plasma Biomarkers
por: Mattsson-Carlgren, Niklas, et al.
Publicado: (2023)

β-Amyloid–Dependent and –Independent Genetic Pathways Regulating CSF Tau Biomarkers in Alzheimer Disease
por: Kumar, Atul, et al.
Publicado: (2022)

Plasma biomarkers of Alzheimer’s disease improve prediction of cognitive decline in cognitively unimpaired elderly populations
por: Cullen, Nicholas C., et al.
Publicado: (2021)

CSF biomarkers of neuroinflammation and cerebrovascular dysfunction in early Alzheimer disease
por: Janelidze, Shorena, et al.
Publicado: (2018)

Clinically Relevant Changes for Cognitive Outcomes in Preclinical and Prodromal Cognitive Stages: Implications for Clinical Alzheimer Trials
por: Borland, Emma, et al.
Publicado: (2022)

Cerebrospinal fluid and plasma biomarker trajectories with increasing amyloid deposition in Alzheimer's disease
por: Palmqvist, Sebastian, et al.
Publicado: (2019)

The implications of different approaches to define AT(N) in Alzheimer disease
por: Mattsson-Carlgren, Niklas, et al.
Publicado: (2020)

Increased amyloidogenic APP processing in APOE ɛ4-negative individuals with cerebral β-amyloidosis
por: Mattsson, Niklas, et al.
Publicado: (2016)

Associations Between CSF Markers of Inflammation, White Matter Lesions, and Cognitive Decline in Individuals Without Dementia
por: Gertje, Eske Christiane, et al.
Publicado: (2023)

Time to Amyloid Positivity and Preclinical Changes in Brain Metabolism, Atrophy, and Cognition: Evidence for Emerging Amyloid Pathology in Alzheimer's Disease
por: Insel, Philip S., et al.
Publicado: (2017)

Comparing a pre-defined versus deep learning approach for extracting brain atrophy patterns to predict cognitive decline due to Alzheimer’s disease in patients with mild cognitive symptoms
por: Arvidsson, Ida, et al.
Publicado: (2023)

Plasma amyloid-β42/40 and apolipoprotein E for amyloid PET pre-screening in secondary prevention trials of Alzheimer’s disease
por: Cullen, Nicholas C, et al.
Publicado: (2023)

Associations between tau, Aβ, and cortical thickness with cognition in Alzheimer disease
por: Ossenkoppele, Rik, et al.
Publicado: (2019)

Association of β-Amyloid Accumulation With Executive Function in Adults With Unimpaired Cognition
por: Tideman, Pontus, et al.
Publicado: (2022)

DOPA decarboxylase is an emerging biomarker for Parkinsonian disorders including preclinical Lewy body disease
por: Pereira, Joana B., et al.
Publicado: (2023)

Greater tau load and reduced cortical thickness in APOE ε4-negative Alzheimer’s disease: a cohort study
por: Mattsson, Niklas, et al.
Publicado: (2018)

Axonal degeneration and amyloid pathology predict cognitive decline beyond cortical atrophy
por: Svenningsson, Anna Linnéa, et al.
Publicado: (2022)

Amyloid-associated increases in soluble tau relate to tau aggregation rates and cognitive decline in early Alzheimer’s disease
por: Pichet Binette, Alexa, et al.
Publicado: (2022)

Plasma tau in Alzheimer disease
por: Mattsson, Niklas, et al.
Publicado: (2016)

Performance of Fully Automated Plasma Assays as Screening Tests for Alzheimer Disease–Related β-Amyloid Status
por: Palmqvist, Sebastian, et al.
Publicado: (2019)

Associations of Plasma Phospho-Tau217 Levels With Tau Positron Emission Tomography in Early Alzheimer Disease
por: Janelidze, Shorena, et al.
Publicado: (2020)

Microglial activation protects against accumulation of tau aggregates in nondemented individuals with underlying Alzheimer’s disease pathology
por: Pereira, Joana B., et al.
Publicado: (2022)

Genetic Moderation of the Association of β-Amyloid With Cognition and MRI Brain Structure in Alzheimer Disease
por: Insel, Philip S., et al.
Publicado: (2023)

Accelerated inflammatory aging in Alzheimer’s disease and its relation to amyloid, tau, and cognition
por: Cullen, Nicholas C., et al.
Publicado: (2021)

Associations of CSF PDGFRβ With Aging, Blood-Brain Barrier Damage, Neuroinflammation, and Alzheimer Disease Pathologic Changes
por: Cicognola, Claudia, et al.
Publicado: (2023)

CSF Aβ42/Aβ40 and Aβ42/Aβ38 ratios: better diagnostic markers of Alzheimer disease
por: Janelidze, Shorena, et al.
Publicado: (2016)

Aβ deposition is associated with increases in soluble and phosphorylated tau that precede a positive Tau PET in Alzheimer’s disease
por: Mattsson-Carlgren, Niklas, et al.
Publicado: (2020)

Cerebrospinal fluid analysis detects cerebral amyloid-β accumulation earlier than positron emission tomography
por: Palmqvist, Sebastian, et al.
Publicado: (2016)

The Effects of Tau, Amyloid, and White Matter Lesions on Mobility, Dual Tasking, and Balance in Older People
por: Nilsson, Maria H, et al.
Publicado: (2020)

Astrocytic function is associated with both amyloid-β and tau pathology in non-demented APOE ϵ4 carriers
por: Spotorno, Nicola, et al.
Publicado: (2022)

Longitudinal plasma p-tau217 is increased in early stages of Alzheimer’s disease
por: Mattsson-Carlgren, Niklas, et al.
Publicado: (2020)

Plasma GFAP is an early marker of amyloid-β but not tau pathology in Alzheimer’s disease
por: Pereira, Joana B, et al.
Publicado: (2021)

Blood‐based biomarkers for Alzheimer's disease
por: Leuzy, Antoine, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_53cf5g8pbgkuv591fasiilk61u